The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: Differential mechanisms of action

British Journal of Pharmacology

Volumn 169, Issue 4, 2013, Pages 808-819

  Kerr, D M ^a   Harhen, B ^a   Okine, B N ^a   Egan, L J ^a   Finn, D P ^a   Roche, M ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

2 AG; brain; cytokines; endocannabinoid; frontal cortex; IL 1 ; IL 10; IL 6; JZL184; monoacylglycerol lipase; NF B; plasma; TNF

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 4 NITROPHENYL 4 [DIBENZO[D][1,3]DIOXOL 5 YL(HYDROXY)METHYL]PIPERIDINE 1 CARBOXYLATE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ACYLGLYCEROL LIPASE; ARACHIDONIC ACID; ESTERASE INHIBITOR; I KAPPA B ALPHA; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; JZL 184; LIPOPOLYSACCHARIDE; PROSTAGLANDIN D2; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FRONTAL CORTEX; MALE; NONHUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RAT; SPLEEN; SYSTEMIC THERAPY;

ANIMALS; ANTI-ANXIETY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACIDS; BENZODIOXOLES; CANNABINOID RECEPTOR ANTAGONISTS; CYTOKINES; ENCEPHALITIS; ENDOCANNABINOIDS; ENZYME INHIBITORS; FRONTAL LOBE; GLYCERIDES; LIPOPOLYSACCHARIDES; MALE; MONOACYLGLYCEROL LIPASES; NERVE TISSUE PROTEINS; PERITONITIS; PIPERIDINES; PROSTAGLANDINS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SPLEEN;

EID: 84878041885     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02237.x     Document Type: Article

References (64)

1. Alexander SP, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC), 5th edn. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Alhouayek M, Lambert DM, Delzenne NM, Cani PD, Muccioli GG, (2011). Increasing endogenous 2-arachidonoylglycerol levels counteracts colitis and related systemic inflammation. FASEB J 25: 2711-2721.
3. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A, et al. (2001). Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15: 300-302.
4. Blankman JL, Simon GM, Cravatt BF, (2007). A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14: 1347-1356.
5. Cable JC, Tan GD, Alexander SP, O'Sullivan SE, (2011). The activity of the endocannabinoid metabolising enzyme fatty acid amide hydrolase in subcutaneous adipocytes correlates with BMI in metabolically healthy humans. Lipids Health Dis 10: 129.
6. Chang YH, Lee ST, Lin WW, (2001). Effects of cannabinoids on LPS-stimulated inflammatory mediator release from macrophages: involvement of eicosanoids. J Cell Biochem 81: 715-723.
7. Chen X, Zhang J, Chen C, (2011). Endocannabinoid 2-arachidonoylglycerol protects neurons against beta-amyloid insults. Neuroscience 178: 159-168.
8. Comelli F, Giagnoni G, Bettoni I, Colleoni M, Costa B, (2007). The inhibition of monoacylglycerol lipase by URB602 showed an anti-inflammatory and anti-nociceptive effect in a murine model of acute inflammation. Br J Pharmacol 152: 787-794.
9. Croci T, Landi M, Galzin AM, Marini P, (2003). Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol 140: 115-122.
10. Di Marzo V, Bisogno T, Sugiura T, Melck D, De Petrocellis L, (1998). The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem J 331 (Pt 1): 15-19.
11. Dinh TP, Carpenter D, Leslie FM, Freund TF, Katona I, Sensi SL, et al. (2002). Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A 99: 10819-10824.
12. Du H, Chen X, Zhang J, Chen C, (2011). Inhibition of COX-2 expression by endocannabinoid 2-arachidonoylglycerol is mediated via PPAR-gamma. Br J Pharmacol 163: 1533-1549.
13. Facchinetti F, Del Giudice E, Furegato S, Passarotto M, Leon A, (2003). Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide. Glia 41: 161-168.
14. Ferrer B, Asbrock N, Kathuria S, Piomelli D, Giuffrida A, (2003). Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur J Neurosci 18: 1607-1614.
15. Finn DP, (2010). Endocannabinoid-mediated modulation of stress responses: physiological and pathophysiological significance. Immunobiology 215: 629-646.
16. Ford GK, Kieran S, Dolan K, Harhen B, Finn DP, (2011). A role for the ventral hippocampal endocannabinoid system in fear-conditioned analgesia and fear responding in the presence of nociceptive tone in rats. Pain 152: 2495-2504.
17. Gallily R, Breuer A, Mechoulam R, (2000). 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. Eur J Pharmacol 406: R5-R7.
18. Gao Y, Vasilyev DV, Goncalves MB, Howell FV, Hobbs C, Reisenberg M, et al. (2010). Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J Neurosci 30: 2017-2024.
19. Gonzalez C, Herradon E, Abalo R, Vera G, Perez-Nievas BG, Leza JC, et al. (2011). Cannabinoid/agonist WIN 55,212-2 reduces cardiac ischaemia-reperfusion injury in Zucker diabetic fatty rats: role of CB2 receptors and iNOS/eNOS. Diabetes Metab Res Rev 27: 331-340.
20. Guindon J, Guijarro A, Piomelli D, Hohmann AG, (2011). Peripheral antinociceptive effects of inhibitors of monoacylglycerol lipase in a rat model of inflammatory pain. Br J Pharmacol 163: 1464-1478.
21. Hohmann AG, Suplita RL, Bolton NM, Neely MH, Fegley D, Mangieri R, et al. (2005). An endocannabinoid mechanism for stress-induced analgesia. Nature 435: 1108-1112.
22. Jayamanne A, Greenwood R, Mitchell VA, Aslan S, Piomelli D, Vaughan CW, (2006). Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 147: 281-288.
23. Jean-Gilles L, Gran B, Constantinescu CS, (2010). Interaction between cytokines, cannabinoids and the nervous system. Immunobiology 215: 606-610.
24. Ji Y, Liu J, Wang Z, Li Z, (2011). PPARgamma agonist rosiglitazone ameliorates LPS-induced inflammation in vascular smooth muscle cells via the TLR4/TRIF/IRF3/IP-10 signaling pathway. Cytokine 55: 409-419.
25. Kerr DM, Burke NN, Ford GK, Connor TJ, Harhen B, Egan LJ, et al. (2012). Pharmacological inhibition of endocannabinoid degradation modulates the expression of inflammatory mediators in the hypothalamus following an immunological stressor. Neuroscience 204: 53-63.
26. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
27. Kinsey SG, Long JZ, O'Neal ST, Abdullah RA, Poklis JL, Boger DL, et al. (2009). Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J Pharmacol Exp Ther 330: 902-910.
28. Kinsey SG, Long JZ, Cravatt BF, Lichtman AH, (2010). Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms. J Pain 11: 1420-1428.
29. Kinsey SG, Nomura DK, O'Neal ST, Long JZ, Mahadevan A, Cravatt BF, et al. (2011). Inhibition of monoacylglycerol lipase attenuates nonsteroidal anti-inflammatory drug-induced gastric hemorrhages in mice. J Pharmacol Exp Ther 338: 795-802.
30. Lang W, Qin C, Hill WA, Lin S, Khanolkar AD, Makriyannis A, (1996). High-performance liquid chromatographic determination of anandamide amidase activity in rat brain microsomes. Anal Biochem 238: 40-45.
31. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, et al. (2009a). Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5: 37-44.
32. Long JZ, Nomura DK, Cravatt BF, (2009b). Characterization of monoacylglycerol lipase inhibition reveals differences in central and peripheral endocannabinoid metabolism. Chem Biol 16: 744-753.
33. Lourbopoulos A, Grigoriadis N, Lagoudaki R, Touloumi O, Polyzoidou E, Mavromatis I, et al. (2011). Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis. Brain Res 1390: 126-141.
34. McCarron RM, Shohami E, Panikashvili D, Chen Y, Golech S, Strasser A, et al. (2003). Antioxidant properties of the vasoactive endocannabinoid, 2-arachidonoyl glycerol (2-AG). Acta Neurochir Suppl 86: 271-275.
35. Maggi Jr LB, Sadeghi H, Weigand C, Scarim AL, Heitmeier MR, Corbett JA, (2000). Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression. Diabetes 49: 346-355.
36. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576
37. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, et al. (1995). Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50: 83-90.
38. Mestre L, Correa F, Docagne F, Clemente D, Guaza C, (2006). The synthetic cannabinoid WIN 55,212-2 increases COX-2 expression and PGE2 release in murine brain-derived endothelial cells following Theiler's virus infection. Biochem Pharmacol 72: 869-880.
39. Molina-Holgado E, Molina-Holgado F, (2010). Mending the broken brain: neuroimmune interactions in neurogenesis. J Neurochem 114: 1277-1290.
40. Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M, (2009). Cannabinoids as novel anti-inflammatory drugs. Future Med Chem 1: 1333-1349.
41. Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC, et al. (2011). Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 334: 809-813.
42. Olango WM, Roche M, Ford GK, Harhen B, Finn DP, (2011). The endocannabinoid system in the rat dorsolateral periaqueductal grey mediates fear-conditioned analgesia and controls fear expression in the presence of nocicpetive tone. Br J Pharmacol 165: 2549-2560.
43. Oleson EB, Beckert MV, Morra JT, Lansink CS, Cachope R, Abdullah RA, et al. (2012). Endocannabinoids shape accumbal encoding of cue-motivated behavior via CB1 receptor activation in the ventral tegmentum. Neuron 73: 360-373.
44. Panikashvili D, Simeonidou C, Ben-Shabat S, Hanus L, Breuer A, Mechoulam R, et al. (2001). An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 413: 527-531.
45. Panikashvili D, Mechoulam R, Beni SM, Alexandrovich A, Shohami E, (2005). CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition. J Cereb Blood Flow Metab 25: 477-484.
46. Panikashvili D, Shein NA, Mechoulam R, Trembovler V, Kohen R, Alexandrovich A, et al. (2006). The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis 22: 257-264.
47. Raman P, Kaplan BL, Thompson JT, Vanden Heuvel JP, Kaminski NE, (2011). 15-Deoxy-delta12,14-prostaglandin J2-glycerol ester, a putative metabolite of 2-arachidonyl glycerol, activates peroxisome proliferator activated receptor gamma. Mol Pharmacol 80: 201-209.
48. Read MA, Whitley MZ, Williams AJ, Collins T, (1994). NF-kappa B and I kappa B alpha: an inducible regulatory system in endothelial activation. J Exp Med 179: 503-512.
49. Roche M, Diamond M, Kelly JP, Finn DP, (2006). In vivo modulation of LPS-induced alterations in brain and peripheral cytokines and HPA axis activity by cannabinoids. J Neuroimmunol 181: 57-67.
50. Roche M, Kelly JP, O'Driscoll M, Finn DP, (2008). Augmentation of endogenous cannabinoid tone modulates lipopolysaccharide-induced alterations in circulating cytokine levels in rats. Immunology 125: 263-271.
51. Rockwell CE, Snider NT, Thompson JT, Vanden Heuvel JP, Kaminski NE, (2006). Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol Pharmacol 70: 101-111.
52. Ryberg E, Larsson N, Sjogren S, Hjorth S, Hermansson NO, Leonova J, et al. (2007). The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152: 1092-1101.
53. Savinainen JR, Saario SM, Laitinen JT, (2012). The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. Acta Physiol (Oxf) 204: 267-276.
54. Sciolino NR, Zhou W, Hohmann AG, (2011). Enhancement of endocannabinoid signaling with JZL184, an inhibitor of the 2-arachidonoylglycerol hydrolyzing enzyme monoacylglycerol lipase, produces anxiolytic effects under conditions of high environmental aversiveness in rats. Pharmacol Res 64: 226-234.
55. Smith SR, Terminelli C, Denhardt G, (2000). Effects of cannabinoid receptor agonist and antagonist ligands on production of inflammatory cytokines and anti-inflammatory interleukin-10 in endotoxemic mice. J Pharmacol Exp Ther 293: 136-150.
56. Stella N, (2009). Endocannabinoid signaling in microglial cells. Neuropharmacology 56: 244-253.
57. van der Stelt M, Fox SH, Hill M, Crossman AR, Petrosino S, Di Marzo V, et al. (2005). A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J 19: 1140-1142.
58. van der Stelt M, Mazzola C, Esposito G, Matias I, Petrosino S, De Filippis D, et al. (2006). Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell Mol Life Sci 63: 1410-1424.
59. Sticht MA, Long JZ, Rock EM, Limebeer CL, Mechoulam R, Cravatt BF, et al. (2011). The MAGL inhibitor, JZL184, attenuates LiCl-induced vomiting in the Suncus murinus and 2AG attenuates LiCl-induced nausea-like behavior in rats. Br J Pharmacol 165: 2425-2435.
60. Ullrich O, Merker K, Timm J, Tauber S, (2007). Immune control by endocannabinoids-New mechanisms of neuroprotection? J Neuroimmunol 184: 127-135.
61. Vandevoorde S, Jonsson KO, Labar G, Persson E, Lambert DM, Fowler CJ, (2007). Lack of selectivity of URB602 for 2-oleoylglycerol compared to anandamide hydrolysis in vitro. Br J Pharmacol 150: 186-191.
62. Xie S, Borazjani A, Hatfield MJ, Edwards CC, Potter PM, Ross MK, (2010). Inactivation of lipid glyceryl ester metabolism in human THP1 monocytes/macrophages by activated organophosphorus insecticides: role of carboxylesterases 1 and 2. Chem Res Toxicol 23: 1890-1904.
63. Ye L, Zhang B, Seviour EG, Tao KX, Liu XH, Ling Y, et al. (2011). Monoacylglycerol lipase (MAGL) knockdown inhibits tumor cells growth in colorectal cancer. Cancer Lett 307: 6-17.
64. Zhang J, Chen C, (2008). Endocannabinoid 2-arachidonoylglycerol protects neurons by limiting COX-2 elevation. J Biol Chem 283: 22601-22611.